The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Adherence to adjuvant immunotherapy and TKIs in resected in NSCLC
Francesco Guerrera, MD, University of Turin, Turin, Italy, provides an overview of a meta-analysis assessing adherence to adjuvant immunotherapy and tyrosine kinase inhibitors (TKIs) in resected non-small cell lung cancer (NSCLC). A high rate of incomplete treatment course completion was reported but no significant differences in therapy adherence or adverse events were found between immunotherapy and TKIs. The findings highlight the need for optimizing adjuvant therapy protocols to improve completion rates and minimize toxicity. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
